The FDA has accepted a new drug application for the intravesical solution of UGN-102 in low-grade intermediate-risk ...

This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patients. CNAs ...

GEORGIA AVENUE, WA, UNITED STATES, October 17, 2024 /EINPresswire / -- The latest release from Vantage <a target=_blank href= ...

Electronic nudges had a small impact on flu vaccine uptake in patients without diabetes but showed no significant effect ...

This technology quickly and sensitively detects metabolites and changes in cancer patients' body fluids, providing a non-invasive way to diagnose cancer instead of traditional blood draws or biopsies.